Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


16. March 2021 | 07:16 CET

Bayer, Cardiol Therapeutics, Xiaomi - Biotech: Blockbuster potential here!

  • Biotechnology
Photo credits: pixabay.com

Germany is leading the race for a vaccine against the coronavirus With two companies - BioNTech and CureVac. The biotech industry is currently experiencing a growth spurt that will continue over the next few years, if not decades. In Germany alone, EUR 7 billion is invested annually in research and development. The goal is to develop new therapies to prevent, alleviate and cure diseases. The opportunity for disproportionate share price gains by investing in a company at an early stage of research is gigantic.

time to read: 3 minutes by Stefan Feulner
ISIN: DE000BAY0017 , CA14161Y2006 , KYG9830T1067


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


Rocky road ahead

Developing new drugs is a lengthy process. Out of 5,000 to 10,000 hopefuls tested in pharmaceutical companies' research laboratories, on average, only one ends up as a finished drug in the pharmacy. Between them, there is an average period of 13.5 years. In between, there are 3 phases: In the preclinical study, the drug candidate is tested on cell cultures and animals, while in phase 2 clinical trial, the drug is tested on humans for the first time. In phase 3, doctors test the drug on thousands of patients to see whether efficacy and safety can be confirmed in many different patients. Interactions with other drugs will also be studied. Once a new drug has passed all the prescribed studies and tests, the biotech company finally applies for drug approval from the relevant authorities.

Potential in the boom market

The Company Cardiol Therapeutics has already come a long way. The Canadians are focused on manufacturing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart disease. These include acute myocarditis and other causes of heart failure. The focus is on the product CardiolRx, which is already in Phase 2/3 clinical trials. CardiolRx is a pharmaceutically manufactured oral cannabidiol formulation. The objective is to evaluate the compound's efficacy and safety as a cardio-protective therapy to reduce mortality and serious heart disease in COVID-19 patients with pre-existing cardiovascular disease and risk and assess the compound's impact on key markers of inflammatory heart disease.

Comparison with USA lags

The current stock market valuation of Cardiol Therapeutics, which has other CBD drugs in development in addition to the blockbuster candidate CardiolRx, currently has a market value of just under EUR 80 million. If one compares US biotechs in a comparable development phase, there should still be considerable potential here. To present itself to a broader circle of investors, the management has applied for a Nasdaq listing. Another positive fact is that the Company receives CAD 10 million from the exercise of warrants and stock options to be used for further development steps.

Focus on growth

With the glyphosate settlement behind it, one must look ahead. In the coming years, the pharmaceutical and agricultural group Bayer intends to accelerate its growth and improve its profitability. According to the Company's headquarters, this will be achieved through new innovations. However, the all-important question is how the legal dispute in the Monsanto takeover course will end. Here, Bayer CEO Werner Baumann expects a possible agreement at the end of June at the earliest. Despite the vague statements concerning the expected settlement, analysts remain positive. The US analyst firm Bernstein Research maintains a "buy" rating on Bayer shares and assigns a price target of EUR 69.00. NordLB raised its price target from EUR 61.00 to EUR 64.00. The experts see the ongoing transformation process, the positioning of the three divisions and the initiated efficiency program as positive.

The tide is turning

A points victory for Chinese technology Group Xiaomi. The Department of Defense had blacklisted Xiaomi shortly before President Donald Trump's term ended amid allegations of ties to the Chinese military. Xiaomi denies the allegations. A judge suspended the punitive measures, and the court said the reasons were based on inadequate justification by the US Department of Defense. Important for Xiaomi is the fact that US investors are now allowed to reinvest in the papers of the current number three smartphone manufacturer in the world. In addition, the Company announced a new USD 1.29 billion share buyback program last week. Management believes that a share buyback under current conditions demonstrates the Company's confidence in its business prospects and creates value for shareholders. It's good timing. After all, Xiaomi has lost a whopping 40% since January.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read